Compound News and Research

RSS

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

First Edition: August 26, 2009 - Kennedy dies

Today's headlines focus on the overnight death of Senator Edward Kennedy and his career as one of Washington's most influential lawmakers.

26 Aug 2009

ConjuChem Biotechnologies completes non-dilutive capital transaction

ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) today announced the completion of the transaction providing $5 million in new, non-dilutive capital to the Company. The Superior Court of Québec has approved the previously announced plan of arrangement (the "Arrangement") under section 192 of the Canada Business Corporations Act (the "CBCA") involving ConjuChem and Colabor Income Fund ("Colabor"), among others, all as fully described in ConjuChem's management information circular dated July 17, 2009.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Study reveals high levels of ergothioneine in RBCs of women with pre-eclampsia

A chemical compound found in unpasteurised food has been detected in unusually high levels in the red blood cells of pregnant women with the condition pre-eclampsia.

26 Aug 2009

All funding for Miami-Dade community-based organizations cut by Mayor Alvarez

Miami-Dade County Mayor Alvarez has eliminated all funding for community-based organizations (CBOs) for FY 2009-10, effective October 1, 2009. The proposed would mean the total elimination of over $31 million in grants to community-based organizations in Miami-Dade County. A significant portion of the CBO cuts would apply to Institute for Child & Family Health (ICFH) the largest provider of children's services in the County.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Second-quarter results enable Meridian achieve a 3-year compound annual growth rate of 72.8 percent

Meridian announced today strong results for the second quarter of 2009, with this being the second consecutive quarter of exceptional revenue and earnings. These results will undoubtedly help Meridian and its parent company, Visionary Integration Professionals (VIP), end 2009 with an exceptional three-year compound annual growth rate (CAGR). Between 2008 and 2005, Meridian and VIP posted a CAGR of 72.8 percent.

24 Aug 2009

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

NovaBay(R) Pharmaceuticals, Inc., a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

24 Aug 2009

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera’s JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.

24 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute's (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate and accelerate the discovery and development of new therapeutic agents to treat cancer patients. Southern Research will establish one of NCI's five Comprehensive Chemical Biology Centers at its Birmingham campus.

21 Aug 2009

New strategy found to increase the efficacy of protein-based drugs

A new method for attaching a large protective polymer molecule to a protein appears to improve protein drugs significantly.

20 Aug 2009

Wireless patient monitoring systems tends to be more economical according to ABI Research

The market for wireless devices that monitor patients’ condition and report that data to healthcare providers is on the verge of explosive growth, according to a new study from ABI Research. Over the next few years it will show a remarkable 77% compound annual growth rate (CAGR) resulting in global revenue of almost $950 million in 2014.

20 Aug 2009

Arzoxifene phase 3 study results reported by Lilly

Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

19 Aug 2009

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

18 Aug 2009

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Two nanoscale devices recently reported by University of Pittsburgh researchers in two separate journals harness the potential of carbon nanomaterials to enhance technologies for drug or imaging agent delivery and energy storage systems, in one case, and, in the other, bolster the sensitivity of oxygen sensors essential in confined settings, from mines to spacecrafts.

17 Aug 2009

U.S. District Court rules against Lilly regarding Gemzar patent

Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

17 Aug 2009

Compound News and Research

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

First Edition: August 26, 2009 - Kennedy dies

ConjuChem Biotechnologies completes non-dilutive capital transaction

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Study reveals high levels of ergothioneine in RBCs of women with pre-eclampsia

All funding for Miami-Dade community-based organizations cut by Mayor Alvarez

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Second-quarter results enable Meridian achieve a 3-year compound annual growth rate of 72.8 percent

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

Lundbeck to launch Sabril in the US following FDA's NDA approval

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

New strategy found to increase the efficacy of protein-based drugs

Wireless patient monitoring systems tends to be more economical according to ABI Research

Arzoxifene phase 3 study results reported by Lilly

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

U.S. District Court rules against Lilly regarding Gemzar patent

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News